AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...

Amgen Inc. (NASDAQ:AMGN ... EVENITY, which targets osteoporosis in postmenopausal women, and Repatha, which addresses heart disease and cholesterol, are two medications that consistently provide ...